Clinical trials: COVID19 ARDS
Coronavirus Infection, Pneumonia, Viral
COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Most cases are mild or asymptomatic.
- Conditions
- Coronavirus Infection, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- CoDEX (NCT04327401)
- Testing
- Dexamethasone
- Where
- 21 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Hospital Sirio-Libanes
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Covid19, ARDS
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute…
- Conditions
- Covid19, ARDS, Hypoxia, Cytokine Storm
- Trial name
- NCT04657458
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Covid19, ARDS
Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19
A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19).
- Trial name
- NCT04499313
- Testing
- Dexamethasone, Methylprednisolone
- Where
- 2 sites in Bangladesh
- Volunteers
- 60 people
- Sponsor
- Chattogram General Hospital
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Corona Virus Infection, COVID-19
Zofin (Organicell Flow) for Patients With COVID-19
The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
- Conditions
- Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04384445
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
Corona Virus Infection, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Early-initiated High Flow Oxygen Therapy vs Conventional Oxygen Therapy Among Patients With ARDS in the Course of SARS-CoV2 Pneumonia.
The aim of the study is to compare two methods of oxygen therapy in patients with acute respiratory distress syndrome in the course of SARS-CoV2 pneumonia.
- Conditions
- Corona Virus Infection, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, Oxygen Deficiency
- Trial name
- NCT05197686
- Testing
- Oxygen theraphy with high flow nasal cannule, Oxygen theraphy with mask with reservoir
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
ARDS, Covid19
Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)
Prone positioning is one of the few therapies known to improve mortality in ARDS. Traditionally, patients are proned for 16 hours per 24 hour period. Some retrospective data suggests improvement may persist beyond 16 hours.
- Conditions
- ARDS, Covid19, Acute Hypoxemic Respiratory Failure
- Trial name
- NCT04581811
- Testing
- Prolonged Proned Positioning, Traditional Proning Arm
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Coronavirus Infections, Pneumonia, Viral
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019.
- Conditions
- Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- NoCovid (NCT04305457)
- Testing
- Nitric Oxide
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Covid19, Corona Virus Infection
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease…
- Conditions
- Covid19, Corona Virus Infection, ARDS, Aviptadil
- Trial name
- NCT04536350
- Testing
- Aviptadil 67μg
- Where
- 2 sites in Switzerland
- Volunteers
- 83 people
- Sponsor
- Prof. Dr. Jörg Leuppi
COVID-19, Coronavirus Disease 2019
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
- Trial name
- NCT04459325
- Testing
- Tigerase® and best available care, Best available care
- Where
- 6 sites in Russia
- Volunteers
- 100 people
- Sponsor
- AO GENERIUM
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina
Coronavirus, Respiratory Distress Syndrome
LIBERATE Trial in COVID-19
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
- Conditions
- Coronavirus, Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- LIBERATE (NCT04334629)
- Testing
- Ibuprofen
- Where
- United Kingdom
- Sponsor
- King's College London
SARS-CoV 2 Pneumonia
Long Term Effects of Awake Prone Positioning in COVID-19 ICU Patients
Long term follow up of patients included in a randomized controlled trial evaluating awake prone positioning among patients suffering SARS-CoV2 pneumonia (NCT04358939)
- Trial name
- Long-termAPP (NCT06080737)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 137 people
- Sponsor
- University Hospital, Tours
Acute Respiratory Distress Syndrome, Covid19
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19
Acute myocardial injury has been a finding of variable frequency among patients diagnosed with COVID-19. It is now recognized that cTnI levels are strongly associated with increased mortality.
- Conditions
- Acute Respiratory Distress Syndrome, Covid19, Myocardial Injury
- Trial name
- PREMIER (NCT04760821)
- Testing
- Trimetazidine
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Ministry of Health, Brazil
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients.
- Trial name
- I-SPY_COVID (NCT04488081)
- Testing
- Remdesivir, Imatinib Mesylate, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Covid19, Functional Capacity
Functional Capacity in Survivors of COVID-19 Related ARDS
Acute respiratory distress syndrome survivors frequently develop impaired physical function, muscle weakness and quality of life.
- Conditions
- Covid19, Functional Capacity, Post-intensive Care Syndrome
- Trial name
- NCT04952844
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Koç University